HALOZYME THERAPEUTICS, INC. (HALO) Form 10-Q Quarterly Reports
HALOZYME THERAPEUTICS, INC. (HALO) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: HALO
CIK: 1159036
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
Ernst & Young LLP
Auditor SinceSince 12/31/2016 12:00:00 AM
Lead Engagement PartnerJohn Faulkner
Audit LocationSan Diego, California, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-10-08 | 2026-10-06 | FORM 4 | 0001159036-26-000140 | View SEC Doc Filr Page |
| 4/A | 2026-10-08 | 2026-05-05 | FORM 4/A | 0001159036-26-000139 | View SEC Doc Filr Page |
| 4 | 2026-10-02 | 2026-10-01 | FORM 4 | 0001159036-26-000136 | View SEC Doc Filr Page |
| 3 | 2026-10-02 | 2026-09-28 | FORM 3 | 0001159036-26-000135 | View SEC Doc Filr Page |
| 4 | 2026-10-02 | 2026-10-01 | FORM 4 | 0001159036-26-000133 | View SEC Doc Filr Page |
| 8-K | 2026-09-30 | 2026-09-28 | 8-K | 0001159036-26-000128 | View SEC Doc Filr Page |
| 8-K | 2026-09-22 | 2026-09-22 | 8-K | 0001193125-26-398015 | View SEC Doc Filr Page |
| 8-K | 2026-09-18 | 2026-09-17 | 8-K | 0001159036-26-000126 | View SEC Doc Filr Page |
| 4 | 2026-09-17 | 2026-09-16 | FORM 4 | 0001159036-26-000123 | View SEC Doc Filr Page |
| 144 | 2026-09-16 | — | 144 Filing | 0001950047-26-009587 | View SEC Doc Filr Page |
| 8-K | 2026-09-16 | 2026-09-16 | 8-K | 0001159036-26-000121 | View SEC Doc Filr Page |
| 4 | 2026-09-11 | 2026-09-09 | FORM 4 | 0001159036-26-000119 | View SEC Doc Filr Page |
| 4 | 2026-09-02 | 2026-09-01 | FORM 4 | 0001159036-26-000117 | View SEC Doc Filr Page |
| 3 | 2026-08-21 | 2026-08-14 | FORM 3 | 0001159036-26-000115 | View SEC Doc Filr Page |
| 4 | 2026-08-19 | 2026-08-17 | FORM 4 | 0001159036-26-000108 | View SEC Doc Filr Page |
| 8-K | 2026-08-18 | 2026-08-14 | 8-K | 0001159036-26-000106 | View SEC Doc Filr Page |
| 144 | 2026-08-17 | — | 144 Filing | 0001968582-26-000846 | View SEC Doc Filr Page |
| 144 | 2026-08-11 | — | 144 Filing | 0001950047-26-007986 | View SEC Doc Filr Page |
| 4 | 2026-08-11 | 2026-08-10 | FORM 4 | 0001662521-26-000002 | View SEC Doc Filr Page |
| 144 | 2026-08-10 | — | 144 Filing | 0001950047-26-007890 | View SEC Doc Filr Page |
| 10-Q | 2026-08-06 | 2026-06-30 | 10-Q | 0001159036-26-000104 | View SEC Doc Filr Page |
| 8-K | 2026-08-06 | 2026-08-06 | 8-K | 0001159036-26-000103 | View SEC Doc Filr Page |
| 4 | 2026-07-09 | 2026-07-08 | FORM 4 | 0001159036-26-000100 | View SEC Doc Filr Page |
| 4 | 2026-07-02 | 2026-06-30 | FORM 4 | 0001159036-26-000096 | View SEC Doc Filr Page |
| 4 | 2026-07-02 | 2026-07-01 | FORM 4 | 0001159036-26-000095 | View SEC Doc Filr Page |